MX2012007341A - Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso. - Google Patents

Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.

Info

Publication number
MX2012007341A
MX2012007341A MX2012007341A MX2012007341A MX2012007341A MX 2012007341 A MX2012007341 A MX 2012007341A MX 2012007341 A MX2012007341 A MX 2012007341A MX 2012007341 A MX2012007341 A MX 2012007341A MX 2012007341 A MX2012007341 A MX 2012007341A
Authority
MX
Mexico
Prior art keywords
purification
preparation
processes
proteasome inhibitors
proteasome
Prior art date
Application number
MX2012007341A
Other languages
English (en)
Inventor
Renee Caroline Roemmele
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2012007341A publication Critical patent/MX2012007341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona ésteres borónicos de la Fórmula I (Ver Formula) en donde R1, R2, R3 y son como se describe en la presente, y métodos para su preparación y purificación.
MX2012007341A 2009-12-22 2010-12-22 Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso. MX2012007341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28895709P 2009-12-22 2009-12-22
PCT/US2010/061695 WO2011087822A1 (en) 2009-12-22 2010-12-22 Proteasome inhibitors and processes for their preparation, purification and use

Publications (1)

Publication Number Publication Date
MX2012007341A true MX2012007341A (es) 2012-07-20

Family

ID=43530797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007341A MX2012007341A (es) 2009-12-22 2010-12-22 Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.

Country Status (10)

Country Link
US (1) US8541590B2 (es)
EP (1) EP2516449A1 (es)
JP (1) JP5783659B2 (es)
CN (1) CN102725300B (es)
AU (1) AU2010341530B2 (es)
CA (1) CA2785300A1 (es)
IL (1) IL220190A0 (es)
MX (1) MX2012007341A (es)
NZ (1) NZ600786A (es)
WO (1) WO2011087822A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041324A1 (en) 2012-09-11 2014-03-20 Cipla Limited Process for preparing of bortezamib
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
KR20190127681A (ko) 2017-02-17 2019-11-13 프레세니어스 카비 온콜로지 리미티드 붕소산 에스테르의 개선된 제조방법
EP3600333A4 (en) * 2017-03-21 2020-11-25 The Scripps Research Institute CU AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301354A1 (de) 1983-01-18 1984-07-19 Matth. Hohner Ag, 7218 Trossingen Elektronisches musikinstrument
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
WO1994017816A1 (en) 1993-02-10 1994-08-18 The President And Fellows Of Harvard College Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
WO1994025051A1 (en) 1993-04-30 1994-11-10 Merck & Co., Inc. Thrombin inhibitors
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
AU687449B2 (en) 1993-10-01 1998-02-26 Aventis Inc. Inhibitors of beta-amyloid protein production
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
JP2002508321A (ja) 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
EP1053750A1 (en) 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
EP1173413B1 (en) 1999-04-27 2004-06-30 Novartis AG Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2001002601A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
WO2001020995A1 (en) 1999-09-23 2001-03-29 Washington University Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof
EP1477180A1 (en) 1999-10-20 2004-11-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2002008187A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US20040106539A1 (en) 2000-10-12 2004-06-03 Ulrich Schubert Agents for the treatment of viral infections
PT3078667T (pt) 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
BR0208786A (pt) 2001-04-09 2004-03-09 Allan Christian Shaw Métodod para identificação de proteìnas de bactérias intracelulares
US7214769B2 (en) 2001-05-23 2007-05-08 The Curators Of The University Of Missouri Method for inverse solid phase synthesis of peptides
CA2446282A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
AU2002324734A1 (en) 2001-08-16 2003-03-03 Levente Fabry-Asztalos Borinic acid protease inhibitors
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
RS53259B (sr) 2004-03-30 2014-08-29 Millennium Pharmaceuticals Inc. Sinteza bortezomiba
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2178888B1 (en) 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors

Also Published As

Publication number Publication date
CN102725300A (zh) 2012-10-10
US8541590B2 (en) 2013-09-24
IL220190A0 (en) 2012-07-31
AU2010341530B2 (en) 2016-03-10
WO2011087822A1 (en) 2011-07-21
EP2516449A1 (en) 2012-10-31
JP2013515082A (ja) 2013-05-02
US20120270840A1 (en) 2012-10-25
AU2010341530A1 (en) 2012-07-19
CA2785300A1 (en) 2011-07-21
JP5783659B2 (ja) 2015-09-24
NZ600786A (en) 2013-12-20
CN102725300B (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
TN2011000673A1 (en) Bace inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
ZA201209297B (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
MX2012008141A (es) Compuestos y metodos.
MY153915A (en) Organic compounds
MY150542A (en) Cmet inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MX2012004780A (es) Inhibidores de akt.
MY169267A (en) New aryl-quinoline derivatives
MX2011011272A (es) Procesos e intermediarios.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
TN2011000355A1 (en) Novel microbiocides
MX2011013790A (es) Derivados de flavina.
GB201107985D0 (en) Process
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX342311B (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).

Legal Events

Date Code Title Description
FG Grant or registration